Inhibitors of histone deacetylase (HDAC), which act to upregulate histone acetylation levels, can improve cognitive performance in Alzheimer's disease models (Graff et al, 2012). This evidence concerns the gene HDAC9 and early-onset autosomal dominant Alzheimer disease.